• 1691 Citations
  • 23 h-Index
19982020
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Sarah A Holstein is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 4 Similar Profiles
Multiple Myeloma Medicine & Life Sciences
Terpenes Medicine & Life Sciences
Farnesyltranstransferase Medicine & Life Sciences
Diphosphonates Medicine & Life Sciences
Protein Prenylation Medicine & Life Sciences
Triazoles Medicine & Life Sciences
Lovastatin Medicine & Life Sciences
Biosynthetic Pathways Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1998 2020

Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling

Holstein, S. A., Al-Kadhimi, Z., Costa, L. J., Hahn, T., Hari, P., Hillengass, J., Jacob, A., Munshi, N. C., Oliva, S., Pasquini, M. C., Shi, Q., Stadtmauer, E. A., Waldvogel, S. L. & McCarthy, P. L., Jan 2020, In : Biology of Blood and Marrow Transplantation. 26, 1, p. e7-e15

Research output: Contribution to journalReview article

Residual Neoplasm
Bone Marrow
Clinical Trials
Transplants
Education

A patent review of bisphosphonates in treating bone disease

Holstein, S. A., May 4 2019, In : Expert Opinion on Therapeutic Patents. 29, 5, p. 315-325 11 p.

Research output: Contribution to journalArticle

Bone Diseases
Diphosphonates
Protein Prenylation
Farnesyltranstransferase
Bone and Bones
1 Citation (Scopus)

Commentary on “Is posttransplant lenalidomide the standard-of-care after an autotransplant for plasma cell myeloma” by Giovanni Barosi and Robert Peter Gale

Holstein, S. A., Suman, V. J. & McCarthy, P. L., Feb 1 2019, In : Leukemia. 33, 2, p. 565-566 2 p.

Research output: Contribution to journalComment/debate

Autografts
Standard of Care
Multiple Myeloma
lenalidomide
1 Citation (Scopus)

Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter?

Kothari, S., Hillengass, J., McCarthy, P. L. & Holstein, S. A., Feb 15 2019, In : Current Hematologic Malignancy Reports. 14, 1, p. 39-46 8 p.

Research output: Contribution to journalReview article

Residual Neoplasm
Multiple Myeloma
Clinical Trials
Disease-Free Survival
Biomarkers
4 Citations (Scopus)

Inhibition of geranylgeranyl diphosphate synthase is a novel therapeutic strategy for pancreatic ductal adenocarcinoma

Haney, S. L., Varney, M. L., Chhonker, Y. S., Shin, S., Mehla, K., Crawford, A. J., Smith, H. J., Smith, L. M., Murry, D. J., Hollingsworth, M. A. & Holstein, S. A., Jun 27 2019, In : Oncogene. 38, 26, p. 5308-5320 13 p.

Research output: Contribution to journalArticle

Farnesyltranstransferase
Adenocarcinoma
Mucins
Unfolded Protein Response
Terpenes